Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2025
2024
2023
2022
2021
2020
2019

2024.02.27

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

2024.02.09

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

2024.01.16

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

2024.01.04

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

2023.11.03

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 15 of 80

Shareholder Tools

© 2025 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn